SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001062993-18-003174
Filing Date
2018-08-08
Accepted
2018-08-08 07:00:50
Documents
10
Period of Report
2018-08-08

Document Format Files

Seq Description Document Type Size
1 FORM 6-K form6k.htm 6-K 5550
2 EXHIBIT 99.1 exhibit99-1.htm EX-99.1 325337
3 EXHIBIT 99.2 exhibit99-2.htm EX-99.2 273730
4 EXHIBIT 99.3 exhibit99-3.htm EX-99.3 7186
5 EXHIBIT 99.4 exhibit99-4.htm EX-99.4 7174
6 EXHIBIT 99.5 exhibit99-5.htm EX-99.5 20310
7 GRAPHIC exhibit99-1x1x1.jpg GRAPHIC 6054
8 GRAPHIC exhibit99-2x1x1.jpg GRAPHIC 6123
9 GRAPHIC exhibit99-2x5x1.jpg GRAPHIC 23369
10 GRAPHIC exhibit99-2x6x1.jpg GRAPHIC 33101
  Complete submission text file 0001062993-18-003174.txt   735401
Mailing Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9
Business Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9 (416) 595-0627
Trillium Therapeutics Inc. (Filer) CIK: 0001616212 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1214
Type: 6-K | Act: 34 | File No.: 001-36596 | Film No.: 18999742
SIC: 2834 Pharmaceutical Preparations